INTRODUCTION
============

To avoid the initiation or progression of visual field defects, the reduction of intraocular pressure (IOP) is the aim of treatment for all glaucoma patients. Surgical treatment is the next step after initial medical treatment (MT) failure. Trabeculectomy is still the gold standard surgery for many specialists ([@b1-cln_68p1376]-[@b5-cln_68p1376]), and proper post-operative management is essential for the achievement of success during the follow-up period. The identification and prompt management of the early aspects of bleb failure are paramount for reducing the rate of ultimate failure of the filtering procedure ([@b6-cln_68p1376]).

Scarring under or over the scleral flap in the subconjunctival space appears to be the most common event leading to filtering failure ([@b7-cln_68p1376],[@b8-cln_68p1376]). Scar tissue formation over the scleral flap in the subconjunctival space or encapsulated bleb (Tenon\'s capsule cyst) formation may occur at any point after the initial surgery. Some authors have suggested encapsulation rates ranging from 13.7% to 29% after trabeculectomy ([@b9-cln_68p1376]-[@b11-cln_68p1376]). Transconjunctival needling revision (TNR), which removes part of the fibroses with a minimally invasive technique and restores filtration, is one treatment option ([@b6-cln_68p1376],[@b12-cln_68p1376]). The use of antifibrotic agents, such as 5- fluorouracil (5-FU) ([@b1-cln_68p1376],[@b5-cln_68p1376],[@b6-cln_68p1376],[@b12-cln_68p1376]) or mitomycin C (MMC) ([@b5-cln_68p1376]), as adjunctives is suggested to increase the procedural success rate. Conversely, several authors have proposed MT with topical hypotensive medication as a successful treatment in patients with encapsulated blebs ([@b13-cln_68p1376]-[@b15-cln_68p1376]).

Several studies ([@b1-cln_68p1376],[@b5-cln_68p1376],[@b12-cln_68p1376]), have reported different success rates and some mixed criteria regarding successful target pressure, bleb morphological features, time of needling procedure, whether single or multiple procedures were performed and whether antifibrotic agents were used.

The purpose of this study was to evaluate the short-term efficacy of early TNR with 5-FU and to compare its outcomes to MT in eyes with encapsulated blebs and uncontrolled IOP after trabeculectomy.

MATERIALS AND METHODS
=====================

We conducted a prospective, randomized interventional study on 40 eyes in 39 patients with encapsulated blebs developed within five months or less after primary trabeculectomy with MMC and IOP ≥ 20 mmHg at the Hospital das Clínicas of the University of São Paulo, Brazil. Data were collected from May 2010 to June 2011. None of the eyes examined in this study received ocular hypotensive agents after the first surgery. An encapsulated bleb was defined as a localized, dome-shaped bleb surrounded by a fibrous tissue called the "ring of steel" ([Figure 1](#f1-cln_68p1376){ref-type="fig"}). Patients were randomized in two groups: TNR with 5-FU and MT. Only one surgeon (RS) performed TNRs. A maximum of two TNRs were allowed.

The study protocol was approved by the Ethics Committee of the Hospital das Clínicas of the University of São Paulo, Brazil. After written informed consent was given and signed, the TNR was performed. Topical anesthetic (tetracaine 0.5%), antibiotic (Ofloxacin 2%) and 5% povidone-iodine solutions were instilled into the eye. A lid speculum was inserted. At the slit lamp, a 27-gauge needle attached to a 1-ml syringe was passed into the subconjunctival space on the opposite site of the scleral flap ([Figure 2](#f2-cln_68p1376){ref-type="fig"}). After that, 0.1 ml of 2% lidocaine with epinephrine was injected. The needle was advanced into a long track towards the cyst to minimize the chance of leakage. Using up-and-down and back-and-forth sweeping movements, the scar tissue was ruptured underneath the conjunctiva, always taking care not to perforate the bleb wall. Then, aqueous flow was reestablished, increasing the bleb size. The needle was removed, and, with a 25-gauge needle attached to an insulin syringe, 5 mg (0.2 ml of 25 mg/ml solution) of 5-FU was subconjunctivally injected superior to the bleb ([Figure 2](#f2-cln_68p1376){ref-type="fig"}).

A topical antibiotic (ofloxacin 2%) was given four times a day for two weeks, and a steroid (prednisolone 1%) was given four times a day and was tapered as clinically indicated.

The intraocular pressure was measured immediately after; one day after; and one, three, six, and twelve months after the procedure. Only the twelve-month IOP was analyzed in this study. All patients were evaluated at the same time (10 am ± one hour) to minimize fluctuation issues.

According to Shin et al. ([@b16-cln_68p1376]), the target intraocular pressure was set for each patient based on the disease progression severity and clinical history. Success was considered as achieving the target pressure, ≤ 18 mmHg, and a 20% reduction from baseline at last follow-up (without any hypotensive agents in the TNR group). The exclusion criterion was the requirement of any further treatments, including medical or surgical procedures. In the MT group, topical hypotensive treatment was initialized with a nonspecific beta-blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonists, as necessary. Systemic medication was not used. The exclusion criterion was the requirement of any further surgical procedures.

The demographic data and characteristics of the study population were collected.

Statistical analyses between variables were performed using the Student\'s t-test for parametric data and chi-square and Mann-Whitney U tests for non-parametric data. Two tailed *p* values \<0.05 were taken to indicate significance. The SPSS software version 15.0 (SPSS Inc., Chicago, IL) was used for statistical analyses.

RESULTS
=======

Among the 40 eyes analyzed during a 12-month time period, 20 were randomized to TNR, and 20 were randomized to MT. In the TNR group, the mean age was 57.30±15.21 years (range 27-83 years). Fifty-five percent of the subjects were female, and 65% were white. In the MT group, the mean age was 63.30±12.01 years (range 27-79 years), 60% were female, and 30% were white ([Table 1](#t1-cln_68p1376){ref-type="table"}). The types of glaucoma are also shown in [Table 1](#t1-cln_68p1376){ref-type="table"}.

The mean times between the filtering surgery and initial treatment after randomization were 43.15±28.71 days (range 17-153 days) in the TNR group and 51.60±30.61 days (range 23-139 days) in the MT group (*p* = 0.34).

The mean IOPs before the initial treatment were 25.15±5.25 mmHg in the TNR group and 25.10±4.36 mmHg in the MT group (*p* = 0.58). The mean IOPs at the 12 month follow-up were 12.14±2.80 mmHg in the TNR group and 15.13±2.07 mmHg in the MT group (p = 0.004) ([Table 2](#t2-cln_68p1376){ref-type="table"}). Fourteen eyes (70%) in the TNR group and 15 eyes (75%) in the MT group were considered successes (*p* = 0.89). Six eyes (30%) were excluded in the TNR group (five required MT and one further surgery), and five eyes (25%) were excluded in the MT group (four required further filtering surgery and one was submitted to the needling procedure) (*p* = 0.79).

The comparison of the IOP distribution before and after the treatment in both groups is shown in [Figure 3](#f3-cln_68p1376){ref-type="fig"} (boxplot).

The mean number of needling procedures in the TNR group was 1.35±0.49, and the mean number of medications in the MT group was 2.15±0.74 at the last follow-up.

Complications after the needling procedure were observed in three eyes (15%). One eye had a flat anterior chamber and hyphema, and one eye had a small choroidal effusion. Both were resolved with conservative treatment. One eye had a flat anterior chamber and a choroidal effusion that required surgical treatment.

DISCUSSION
==========

Several studies have demonstrated the efficacy of needling revision in failing filtering blebs after filtration surgery ([@b1-cln_68p1376]-[@b4-cln_68p1376],[@b2-cln_68p1376],[@b3-cln_68p1376],[@b4-cln_68p1376],[@b16-cln_68p1376]-[@b21-cln_68p1376]). However, as bleb morphology, time of needling, follow-up period and successful criteria are different in each study, comparisons of these studies would not be meaningful.

Multiple bleb morphologies have been present in the majority of studies; encapsulated blebs appear to have better results in comparison to flat blebs ([@b22-cln_68p1376]). Rotchford & King ([@b12-cln_68p1376]) suggested that high blebs were more likely to survive than flat blebs if needling was performed within three months after trabeculectomy. Iwach et al. ([@b20-cln_68p1376]) reported a lower failure rate after the needling procedure in encapsulated blebs (19%) in comparison to diffuse blebs (53%). Interestingly, Broadway et al. ([@b1-cln_68p1376]) reported success rates of 47% for encapsulated blebs and 55% for flat blebs when considering an IOP reduction to less than 22 mmHg as success. To minimize the influence of bleb morphology, we have only considered encapsulated blebs in this study.

The success rate of MT in eyes with encapsulated blebs has been reported to range from 71 to 100% ([@b23-cln_68p1376]-[@b25-cln_68p1376]). Comparisons between MT and surgical revision have been previously reported. Costa et al. ([@b13-cln_68p1376]) compared eyes with encapsulated blebs that were randomized to MT or the needling procedure; at the last follow-up, they reported a mean IOP of 16.09±6.92 mmHg in the eyes receiving MT in comparison to a mean IOP of 18.92±6.39 mmHg in the eyes submitted to the needling procedure in addition to MT. In our study, we reported significantly better results after TNR alone (without medication) in comparison to MT (12.14±2.80 mmHg and 15.13±2.07 mmHg, respectively). The use of adjunctive 5-FU may explain our better results in eyes submitted to TNR. Several studies have shown that the use of adjunctive antifibrotic agents seems to increase the success rates of both MMC and 5-FU ([@b1-cln_68p1376],[@b3-cln_68p1376],[@b17-cln_68p1376],[@b20-cln_68p1376],[@b26-cln_68p1376]).

Although the time between the trabeculectomy and the needling procedure does not seem to be a determinant of success, ([@b1-cln_68p1376]) Rotchford & King ([@b12-cln_68p1376]) reported better results when performing needling revisions within a three-month period after trabeculectomy in elevated blebs. We also performed revisions in elevated blebs (encapsulated) a short period of time after trabeculectomy (51.60±30.61 days).

Complications of the needling procedure after trabeculectomy have been previously reported, but most were considered minor and were resolved spontaneously ([@b18-cln_68p1376],[@b27-cln_68p1376]). Temporary conjunctival leakage, small hyphemas and temporary shallowing of the anterior chamber have been reported ([@b18-cln_68p1376],[@b27-cln_68p1376]). However, some reports have suggested more severe complications when performing needling in flat and scarred blebs ([@b28-cln_68p1376],[@b29-cln_68p1376]). In our study, we observed complications in three eyes (15%); only one eye required further surgical treatment.

In this study, we achieved similar success rates in eyes randomized to MT in comparison to TNR with 5-FU (75% *versus* 70%, respectively). However, a significantly lower mean IOP after TNR was observed. By including only encapsulated blebs in this study, the accuracy of measuring successful treatment was increased through the elimination of variations in morphological characteristics. We suggest that TNR with adjunctive 5-FU without further medical therapy is very effective at maintaining a successful IOP for 12 months. The limitations of this prospective study include the small sample size and the short follow-up period.

In conclusion, over a 12-month follow-up, this study showed that TNR with adjunctive 5-FU is as effective as MT. However, TNR has the advantage of being compliance-free and of recovering previously failed trabeculectomies in eyes with encapsulated blebs.

No potential conflict of interest was reported.
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###### 

Demographic data and characteristics of the study population.

                                                            Transconjunctival needling revision (TNR)   Medical treatment (MT)   *p* value
  --------------------------------------------------------- ------------------------------------------- ------------------------ -----------
  **Age** **(mean ± SD -- range)**                          57.30±15.21 (27-83)                         63.30±12.01 (27-79)      0.17
  **Gender**                                                                                                                     
  Female                                                    11 (55%)                                    12 (60%)                 
  Male                                                      9 (45%)                                     8 (40%)                  0.75
  **Race**                                                                                                                       
  White                                                     13 (65%)                                    6 (30%)                  
  Black                                                     7 (35%)                                     13 (65%)                 
  Asian                                                                                                 1 (5%)                   0.07
  **Glaucoma Type**                                                                                                              
  Primary open angle                                        17 (85%)                                    18 (90%)                 
  Congenital                                                1 (5%)                                      1 (5%)                   
  Inflammatory                                              1 (5%)                                      \-                       
  Pseudoexfoliative                                         \-                                          1 (5%)                   
  Neovascular                                               1 (5%)                                                               0.55
  **Time from last surgery to treatment (days) -- range**   43.15±28.71 (17-153)                        51.60±30.61 (23-139)     0.34

###### 

Average intraocular pressure before and after randomization (at the 12-month follow-up) in the TNR and MT groups.

                                                         Transcojunctival needling revision (TNR)   Medical Treatment (MT)   P value
  ------------------------------------------------------ ------------------------------------------ ------------------------ ---------
  **IOP pre-treatment (mmHg)**                           25.15 ± 5.25                               25.10 ± 4.36             0.58
  **IOP post-treatment at 12-months follow up (mmHg)**   12.14 ± 2.80                               15.13 ± 2.07             0.004

[^1]: All authors have contributed to the data collection and analysis and to the writing of this paper.
